Drug delivery emergency response network
Pharmaceutical industry groups join to launch Rx Response, an initiative to support the continued delivery of medicines in the event of a public health emergency. Efforts will be made to coordinate the delivery of medications to hospitals, but the program will not serve as an additional drug distribution center for patients. Rx Response will provide state and local officials with a phone number and Web site to report pharmaceutical needs and offer industry a forum to identify medication supply risks. Rx Response partner groups include the Pharmaceutical Research and Manufacturers of America, the Biotechnology Industry Organization, the National Association of Chain Drug Stores, the National Community Pharmacists Association, the Healthcare Distribution Management Association, the American Red Cross and the American Hospital Association...
You may also be interested in...
While making money in drug delivery has always been tougher than its boosters have promised, this year's been ugly in new and disturbing ways. The key lessons of Pfizer's abandonment of inhaled insulin and Impax's patent assault on Endo's Opana are that partners are less reliable; the products need to be medically superior to existing ones, not simply more convenient; and generic companies are making inroads into the main bastion of drug-delivery success -- spec pharma.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.